| Literature DB >> 28648777 |
Yuchao Gu1, Claudio P Albuquerque2, Daniel Braas3, Wei Zhang4, Genaro R Villa5, Junfeng Bi2, Shiro Ikegami6, Kenta Masui7, Beatrice Gini8, Huijun Yang2, Timothy C Gahman9, Andrew K Shiau9, Timothy F Cloughesy10, Heather R Christofk3, Huilin Zhou11, Kun-Liang Guan12, Paul S Mischel13.
Abstract
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechanisms are not well understood. Using an unbiased proteomic screen, we identified mTORC2 as a critical regulator of amino acid metabolism in cancer via phosphorylation of the cystine-glutamate antiporter xCT. mTORC2 phosphorylates serine 26 at the cytosolic N terminus of xCT, inhibiting its activity. Genetic inhibition of mTORC2, or pharmacologic inhibition of the mammalian target of rapamycin (mTOR) kinase, promotes glutamate secretion, cystine uptake, and incorporation into glutathione, linking growth factor receptor signaling with amino acid uptake and utilization. These results identify an unanticipated mechanism regulating amino acid metabolism in cancer, enabling tumor cells to adapt to changing environmental conditions.Entities:
Keywords: cancer; glioblastoma; glutamate metabolism; glutathione metabolism; mTORC2; xCT
Mesh：
Substances：
Year: 2017 PMID： 28648777 PMCID： PMC5521991 DOI： 10.1016/j.molcel.2017.05.030
Source DB: PubMed Journal: Mol Cell ISSN： 1097-2765 Impact factor: 17.970